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Chronic Obstructive Pulmonary DiseaseCigarette/tobacco smoke/biomass fuel-induced oxidative and aldehyde/carbonyl stress are intimately associated
with the progression and exacerbation of chronic obstructive pulmonary disease (COPD). Therefore, targeting
systemic and local oxidative stress with antioxidants/redox modulating agents, or boosting the endogenous
levels of antioxidants are likely to have beneﬁcial effects in the treatment/management of COPD. Various antiox-
idant agents, such as thiol molecules (glutathione and mucolytic drugs, such as N-acetyl-L-cysteine and N-
acystelyn, erdosteine, fudosteine, ergothioneine, and carbocysteine), have been reported to modulate various
cellular and biochemical aspects of COPD. These antioxidants have been found to scavenge and detoxify free rad-
icals and oxidants, regulate of glutathione biosynthesis, control nuclear factor-kappaB (NF-kappaB) activation,
and hence inhibiting inﬂammatory gene expression. Synthetic molecules, such as speciﬁc spin traps like α-
phenyl-N-tert-butyl nitrone, a catalytic antioxidant (ECSOD mimetic), porphyrins (AEOL 10150 and AEOL
10113), and a superoxide dismutase mimetic M40419, iNOS and myeloperoxidase inhibitors, lipid peroxidation
inhibitors/blockers edaravone, and lazaroids/tirilazad have also been shown to have beneﬁcial effects by inhibit-
ing cigarette smoke-induced inﬂammatory responses and other carbonyl/oxidative stress-induced cellular alter-
ations. A variety of oxidants, free radicals, and carbonyls/aldehydes are implicated in the pathogenesis of COPD, it
is therefore, possible that therapeutic administration or supplementation of multiple antioxidants and/or boost-
ing the endogenous levels of antioxidants will be beneﬁcial in the treatment of COPD. This review discusses var-
ious novel pharmacological approaches adopted to enhance lung antioxidant levels, and various emerging
beneﬁcial and/or prophylactic effects of antioxidant therapeutics in halting or intervening the progression of
COPD. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
A high-oxygen environment with exogenous pollutants/toxicants
constantly being inhaled through the inhaled breath, signiﬁcantly
challenges the lung tissue. Due to its very high blood supply and
large surface area, the lung is highly susceptible to oxidative stress
mediated injury. In addition, the lung epithelium is constantly ex-
posed to oxidants generated endogenously duringmetabolic reactions
(e.g., frommitochondrial electron transport activation of phagocytes),
as well as to inhaled oxidants in the ambient air, including ozone,
nitrogen dioxide, diesel exhaust, and cigarette smoke.
Generations of reactive oxygen species (ROS), such as superoxide
anion (O2•–) and the hydroxyl radical (•OH) are directly associated
with the oxidative modiﬁcation of proteins, lipids, carbohydrates, and
DNA. Oxidative stress causes cell damage, cell necrosis, apoptosis,
autophagy, remodeling of extracellular matrix and blood vessels,ants and Antioxidant Treatment
iology and Disease Program,
Elmwood Avenue, Rochester,
6 0239.
l rights reserved.endothelial dysfunction, inactivation of antiproteases, premature cellu-
lar senescence, elevated mucus secretion, steroid resistance, unfolded
protein response, cell proliferation, epigenetic changes, autoimmunity,
and skeletal muscle dysfunction. Furthermore, these oxidants also
inﬂuence inﬂammatory responses in the lungs through activation of
transcription factor nuclear factor kappaB (NF-κB), mitogen-activated
protein kinases (MAPK) signal transduction pathways, chromatin
remodeling, and transcription of proinﬂammatory mediator genes
[1–5]. These processes are intricately associated with the progression
of chronic obstructive pulmonary disease (COPD) [3–8]. Hence, in
light of oxidative burden and its consequences in pathogenesis of
COPD, this review is focused on various antioxidant strategies based
on various pharmacological, chemical and functional aspects of thiols,
spin traps, lipid peroxidation and protein carbonylation, and redox
sensor inhibitors, enzyme mimetics, synthetic antioxidants, and redox
sensors (Table 1).
2. COPD causes and pathogenesis
COPD is a major and increasing global health problem and is the
fourth most common cause of death in the developed countries. It is
a disabling condition associated with progressive breathlessness
with a slow decline in lung function. COPD will account for over six
Table 1
Antioxidant therapeutic agents in COPD.
Antioxidant compound
Thiol compounds N-acetyl-L-cysteine (NAC)
N-acystelyn (NAL)
N-isobutyrylcysteine (NIC)
Glutathione esters
S-carboxymethylcysteine (Carbocysteine)
Erdosteine
Fudosteine
Thioredoxin
Procysteine
Ergothioneine
Inducers of glutathione biosynthesis
Nrf2 activators CDDO-imidazolide
Sulforaphane
Chalcones (1,2-diphenyl-2-propen-1-ones)
Glutathione peroxidase and SODs
Mimetics Salen compounds
M40419, M 40403, and M40419
Manganese-metaloporphyrins, such as
AEOL-10113 and AEOL-10150
Metaloporphyrins (MnTBAP)
MnTE-2-PyP
EUK compounds (EUK-189)
Ebselen
BXT-51072 (ALT-2074), and BXT-51077
Lipid peroxidation/protein
carbonylation
inhibitors/blockers
Edaravone (MC-186)
Lazaroids/tirilazad
(U75412E or tirilazad mesylate)
Other antioxidants/enzymes
and oxidant scavengers
Nitrone spin traps (NXY-059, STANZ)
Peroxynitrite decomposition catalysts
(FeTMPyP, FP15)
Porphyrins
Glutaredoxins
Peroxiredoxins
Polyphenols, natural products,
and dietary agents
Polyphenols/ﬂavanoids/natural compounds
(Curcumin, resveratrol, quercetin,
sulforaphane, lycopene, Acai, Apocynin,
omega-3-fatty acid, Vitamin D)
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the third leading cause of death by 2020 worldwide. It is the disease
associated with oxidative stress and inﬂammaging (inﬂammation
and accelerated decline in lung function) when the body's antioxi-
dant defense gradually weakens or declines. Patients with COPD
experience a poorer quality of life, suffering from comorbidities asso-
ciated with cardiovascular, muscular (skeletal) and neurological
problems. These comorbidities are associated with increased oxida-
tive stress.
Cigarette smoke is the major risk factor for the development of
COPD. Cigarette smoke contains an estimated 1015–1017 oxidants/
free radicals and ~4700 different chemical compounds, including
reactive aldehydes and quinones, per puff [9–11]. Other noxious
environmental gases/particles, such as aldehydes/carbonyls, NO2,
SO2, and particulate matters, as well as exposure to second hand to-
bacco smoke, and smoke derived from burning of biomass fuel can
also cause oxidative stress and trigger inﬂammatory responses in
the lungs of a susceptible individual.
COPD can be categorized into four classes of severity based on lung
function [GOLD Guidelines] [1,2,4–6]. Emphysema, chronic bronchitis
with airway obstruction, and small airways disease are the distinct phe-
notypes of COPD, but most patients show a combination of different
overlapping phenotypes. Emphysema is characterized by destruction
of the alveolar septa, loss of elastic recoil, airspace enlargement, and
hence loss of gas diffusion capacity. Chronic bronchitis affects the larger
airways by airway inﬂammation (recruitment of neutrophils, macro-
phages, and other immune-inﬂammatory cells), goblet cell hyperplasia
and mucus hypersecretion. Apart from decline of lung function, COPDpatients experience chronic sputum production (mucus hypersecre-
tion), coughing, and often dyspnea. Small airways diseasemainly affects
the bronchioles featuring airway inﬂammation and metaplasia of Clara
cells. The pathogenesis of COPD involves several processes, such as ox-
idative stress, pulmonary, and systemic inﬂammation, protease/anti-
protease imbalance, breakdown in immunity (autoantibody
production), apoptosis, autophagy, vascular and extracellular matrix
remodeling, impaired tissue repair, alteration of cell proliferation, and
cellular senescence/premature aging. All of these processes are inti-
mately associated with systemic and lung oxidative stress [2] (Fig. 1).
3. Cigarette smoke and oxidants
ROS are virtually produced by all of the cells as a result of metab-
olism within the mitochondria and additionally by inﬂammatory
cells and phagocytes, such as macrophages and neutrophils, as well
as during the immuno-inﬂammatory response against a pathogen.
NADPH (nicotinamide adenine dinucleotide phosphate) oxidase en-
zyme complex, present in phagocytes and epithelial cells, xanthine/
xanthine oxidase system, myeloperoxidase, and the heme peroxi-
dases are the main generators of ROS and have been found to be
elevated in COPD patients [12–14]. Similarly, nitric oxide synthase
generates reactive nitrogen species (RNS) in the form of nitric oxide
(NO). NO can combine with O2•– to form a more damaging peroxyni-
trite anion (ONOO-) leading to formation of nitrotyrosine. It has
now been reported that the physiological action of an oxidant de-
pends on the source of its generation. For example, oxidants derived
from NADPH oxidase mainly participate in cell signaling, while
those produced excessively by mitochondria induce cell damage/
death [15].
Production of ROS by phagocytes can be enhanced by oxidants
present in cigarette smoke leading to the release of inﬂammatory
mediators. Some of these mediators are chemotactic in nature and
lead to the recruitment of neutrophils and other inﬂammatory cells
into the lungs. Smokers and patients with COPD have greater migra-
tion of macrophages and neutrophils into their lungs as compared
to non-smokers. These cells can generate ROS via the activation of
NADPH oxidase complex system, leading to further augmentation of
oxidative stress in lungs of smokers and patients with COPD [2–5].
3.1. Cigarette/tobacco smoke as a source of oxidants and carbonyls
Cigarette smoke contains more than 1015-17 oxidant/free radical
molecules per puff and over 4,700 highly reactive chemical compounds
including aldehydes/carbonyls [9], which adds to the oxidant burden in
current smokers. The gas phase of cigarette smoke contains relatively
short-lived O2•− and NO, which immediately react to form the highly
reactive and toxic peroxynitrite ONOO−. A very high diffusion coefﬁ-
cient of ONOO- allows it to diffuse over a greater distance, thus causing
more tissue damage in lung interstitium/microenvironment at the
site of generation.
The tar phase of cigarette smoke contains organic radicals, such
as long-lived semiquinone and quinone radicals, which can rapidly
react with molecular oxygen in a redox dependent manner leading
to generation of various ROS, such as O2•−, •OH, and H2O2 [10,11].
The aqueous phase of cigarette smoke condensate (simulated as
bronchoalveolar ﬂuids of smokers) may undergo redox recycling for
a considerable period of time in the epithelial lining ﬂuid (ELF) of
smokers [10]. The tar phase is also an effective metal chelator, where-
in iron is chelated to produce tar-semiquinone and tar-Fe2+, which
can generate H2O2 continuously [10].
3.2. Cigarette smoke, lipid peroxidation and protein carbonylation
Systemic and lung formation of protein carbonyls (aldehyde protein
adducts) in response to cigarette smoke-derived lipid peroxides/
Fig. 1. Consequences of oxidative stress in pathogenesis of COPD. Inﬂammatory response is mediated by inhaled and/or cellular oxidants and carbonyls. These oxidants activate
alveolar macrophages, neutrophils, eosinophils, and epithelial cells, leading to augmented endogenous ROS generation, redox imbalance, activation of redox-sensitive transcription
factors, mucus hypersecretion, extracellular matrix and small airway remodeling. ROS can trigger several cellular and molecular events which are involved in pathogenesis of COPD.
These cellular and molecular events can be exploited as targets for pharmacological antioxidant strategies in treatment of COPD.
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COPD. The levels of lipid peroxidation products, such as 8-isoprostane/
F2-isoprostanes are increased in smokers and in patients with COPD
[16]. Furthermore, the levels of these lipid peroxidation products have
been correlated with airway obstruction [16]. 4-hydroxy-2-nonenal
(4-HNE) is a speciﬁc, highly reactive, and diffusible end-product of
lipid peroxidation. 4-HNE forms adducts with cysteine, lysine and
histidine residues of proteins, which are referred as protein car-
bonyls. Increased 4-HNE-modiﬁed protein levels (protein carbonyls)
are present in airway and alveolar epithelial cells and endothelial
cells, and in neutrophils in smokers with airway obstruction com-
pared to subjects without airway obstruction [17]. The increased
level of 4-HNE adducts was inversely correlated with lung function
measured as FEV1, suggesting a role for 4-HNE in the pathogenesis
of COPD. Also, α,β-unsaturated aldehydes (4-HNE and acrolein) con-
tained in cigarette smoke impose oxidative stress and elicit IL-8 re-
lease in pulmonary cells through MAPK activation [18].
3.3. Depletion of antioxidants
Systemic antioxidant capacity is decreased in smokers and in
patients with COPD, which is reﬂected by decreased plasma antioxi-
dants and protein sulfhydryls [19]. This occurs transiently during
smoking and resolves rapidly after smoking cessation. However, low
grade oxidative stress still persists in ex-smokers who develop
COPD. The depletion of antioxidant capacity and antioxidants is due
to the increased release of ROS from peripheral blood neutrophils
and monocytes implying the role of oxidants in the pathogenesis of
COPD. Several other studies have shown the deﬁciency of antioxi-
dants in both plasma and lungs of patients with COPD (reviewed
in [2,4,5,20]). It has also been recently reported that antioxidants,such as uric acid, glutathione (GSH), vitamin E, and ascorbate are de-
creased in smokers, and was associated with the severity of COPD ex-
acerbation [21]. Cigarette smoke irreversibly modiﬁes GSH levels
to GSH-conjugates in airway epithelial cells and epithelial lining ﬂuids
leading to antioxidants deﬁciency and injurious lung response [3–6,20].
Cigarette smoking is shown to block the protective expression of Nrf2/
antioxidant response element (ARE) pathway in peripheral mononu-
clear cells of young heavy smokers favoring inﬂammation [22].
4. Therapeutic strategies for COPD
Tissue injury and inﬂammation due to ROS are common to many
disease pathologies including COPD and this similarity provides a
unique antioxidants therapeutic opportunity wherein numerous
lung diseases may be gradually treated by an agent that can suppress
either the generation of ROS or can neutralize such species or both.
Perhaps this might be true at the onset of the disease progression
and pathogenesis for antioxidants to be considered as pre-emptying
agents. Nevertheless, overwhelming evidence suggests that oxida-
tive/carbonyl stress is intimately involved with the pathogenesis of
COPD. A rationale approach for the treatment of COPD would, there-
fore, be to consider antioxidant intervention, not only to neutralize
the excessive oxidative stress, inhibit peroxidation of lipids, and the
subsequent inﬂammatory response, but also to identify the source
of oxidants and overwhelm their generation. This can be achieved
by two approaches, either by increasing the endogenous antioxidant
enzyme defenses or by enhancing the non-enzymatic defenses
through dietary or pharmacological means. Several small-molecular
weight antioxidant compounds that target oxidant signaling, or
quench cigarette smoke-derived oxidants and reactive aldehydes
are currently being tested clinically and pre-clinically [4,20,23].
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(GSH and mucolytic drugs, such as N-acetyl-L-cysteine (NAC), nacys-
telyn (NAL), erdosteine, fudosteine, and carbocysteine lysine salt),
and ergothioneine have all been reported to scavenge/detoxify free
radicals/oxidants, increase intracellular thiol levels, control NF-κB ac-
tivation, and consequently inhibit inﬂammatory gene expression.
Other compounds include dietary antioxidants, superoxide dismutase
(SOD) mimetics, inhibitors of NADPH oxidases and myeloperoxidase,
and synthetic redox modulating agents. Several strategies either to
increase the expression/activity of the antioxidant enzymes or to
mimic their function by enzyme mimetics have been developed. In
this review, the beneﬁcial and/or prophylactic effects of a variety of
antioxidants are discussed. These antioxidant molecules may have
the potential to be used as pharmacological therapeutic agents in
the management and treatment of COPD. The pros and cons for tar-
geting oxidative stress by antioxidants in treatment of COPD are
given in Table 2.
Dietary antioxidants, such as antioxidant vitamins and
carotenoids (vitamin C, tocopherol, β-carotene), and natural
products-containing dietary polyphenols/ﬂavanoids, and other active
compounds (curcumin, resveratrol, green tea-catechins, quercetin),
lycopene, acai, ginkgo biloba, polyunsaturated fatty acids/omega-3
fatty acid, tocotrienols, alpha-lipoic acid, and apocynin are also im-
portant in the management of oxidative stress imposed by cigarette
smoke in smokers and patients with COPD [4,5]. However, the bene-
ﬁcial effects of these dietary products are not part of this review, but
have been discussed elsewhere [4,5].
5. Antioxidant enzyme mimetics and spin traps
Antioxidants, such as SOD, catalase, and glutathione peroxidase play
an important role in the neutralization of free radicals in the cells. Howev-
er, their expression and activities are altered in the lungs of smokers and
patients with COPD [1–6]. Alterations in antioxidant enzyme activity can
be overcome by small compounds possessing catalytic properties. These
compounds can mimic the activity of a larger enzyme-based molecules,
which are known as enzyme mimetics.
5.1. SOD mimetics
Three classes of manganese (Mn)-containing SOD mimetics
have been developed. The ﬁrst class includes several macrocyclic
Mn(II)-pentaazamacrocyclic ligands, such as M40401, M40403, and
M40419 [24,25]. Mn(III)-metaloporphyrins, such as AEOL-10113 andTable 2
Pros and cons of targeting oxidants with antioxidants in COPD.
Antioxidant Pros Cons
Thiol compounds • Potent mucolytic • Lack of bioavailability
• Mild effects on
exacerbation rates
• Cause bronchoconstriction
• Form thiyl/cysteine radicals
Nrf2 activators • Protection seen in
animal models
• Dramatically degraded in
severe COPD GOLD stages
• Induce a variety of phase II
genes/enzymes
• Carbonylation/oxidation
of Nrf2/Keap1
• Clinical studies are required • Prophylactic-potent
inducer is needed
Targeting ROS using
SOD mimetics
• Protection seen in
animal models
• May impair phagocytosis
• Inhibit ECM remodeling • Alter endogenous redox
homeostasis
• Clinical studies are required
Lipid peroxidation/
protein carbonylation
inhibitors/blockers
• Inhibit lipid peroxidation
chain reactions
• Poor bioavailability
• Clinical studies are required • Low presence at the site
of microenvironmentAEOL-10150 form the second class of SOD mimetics [26,27], and
Mn(III)-salen complexes form the third class. Since the ‘Salens’ are
also reported to have catalase-like activity, they can, therefore, neutral-
ize H2O2 in the cells. In addition, Mn(III)-salen complexes can also de-
compose ONOO- [28]. Therefore, Salens appear to have a non-selective
nature of action, a property attributed to the multivalent state in
which they can exist. In an animal model of lung disease, M40419 has
been shown to signiﬁcantly decrease the markers of oxidative stress
in the lungs, and to block the development of emphysema [24]. Since
studies with recombinant SOD treatment has shown to prevent neutro-
phil inﬂux into the lungs and decrease IL-8 release induced by cigarette
smoking [29], it is therefore, possible that these compounds, which pos-
sess antioxidant enzyme properties, may be used as novel antioxidant/
anti-inﬂammatory drugs in COPD. In an ovalbumin challengedmodel of
airway inﬂammation, AEOL10113 was found to inhibit both airway in-
ﬂammation and airway hyperreactivity [26]. In another study in rats,
AEOL10150was shown to inhibit cigarette smoke-induced lung inﬂam-
mation and decreased lipid peroxidation aswell as generation of ONOO-
[27].
The metalloporphyrin-based catalytic antioxidant, MnTE-2-PyP
(Manganese (III) Meso-Tetrakis-(NMethlypyridinium-2-yl) porphy-
rin) has broad antioxidant properties, and has been reported to
scavenge superoxide, lipid peroxides, ONOO−, and H2O2 [30–32]. In-
ﬂammation and injury induced by a wide variety of factors, such as
radiation, bleomycin, or lipopolysaccharide exposure is also de-
creased by MnTE-2-PyP [33,34]. MnTE-2-PyP also reduces NF-κB
signaling by modulating the redox environment of the cell [33]. The
ability of MnTE-2-PyP to affect such a wide variety of different disease
states has been attributed to its ability to alter inﬂammatory redox
cell signaling [35].
Another SOD/catalase mimetic EUK-189 when administered in
rats subjected to heat stress, improved hepatic functions, redox sta-
tus, decreased oxidative injury, and DNA binding activity of redox re-
sponse transcription factor NF-κB [36]. EUK-189 also preserved the
redox potential in aged heat-stressed rats by maintaining GSH/GSSG
ratios to normal control levels. Furthermore, EUK-189 also increased
the expression of stress-responsive protein, heat shock protein 70
(HSP70) in rats subjected to heat stress [37]. Overexpression of
SOD1 attenuates cigarette smoke- and elastase-mediated emphyse-
ma in mice [38]. Interestingly, a recent observation that sustained
lung activity particularly in pulmonary vascular bed of a novel chime-
ric protein SOD2/3 can be achieved by intratracheal administration in
rats [39]. Therefore, these compounds appear to have potential for
therapeutic use in COPD.
The third type of SOD, extracellular superoxide dismutase (ECSOD
or SOD3) is highly expressed in lungs and vessels [40] and is located
in the extracellular matrix (ECM), the junctions of airway epithelial
cells, the surface of airway smooth muscle, and the lining of blood
vessels of the lung. Since SOD3 scavenges O2•–, it may therefore, play
an important role in oxidative lung damage and injury. It has been
reported that acute loss of SOD3 in adult mice causes death, whereas
overexpression of SOD3 in animals exposed to hyperoxia reduces
mortality, suggesting an essential role of SOD3 for survival against
the lethal effect of hyperoxia [41,42]. In cigarette smoke/elastase in-
duced emphysema mouse model, SOD3 was shown to protect the
lung against pulmonary emphysema, which was attributed to the re-
duction of oxidative ECM fragmentation and oxidative posttransla-
tional modiﬁcations of elastin fragments (leading to autoantibody
production) in the lung [43]. Similarly, a recent study showed that
SOD3 down modulated CS-induced oxidative stress in mouse macro-
phages [44]. Hence, SOD3 may be more effective than other SODs in
management of emphysema or more severe COPD phenotype.
Smoking and COPDwere also found to increase sputum levels of ex-
tracellular superoxide dismutase due to adaptive response [45]. Poly-
morphisms in the SOD3 gene were associated with emphysema, but
not COPD susceptibility, highlighting the importance of phenotype
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of SODmimetic signiﬁcantly attenuated the elastase-induced emphyse-
ma in bothwild-type and SOD3 knockout mice, and the level/activity of
SOD3 was decreased in the emphysematous mouse lung [43]. As men-
tioned above, SOD3 was also reported to protect against oxidative frag-
mentation of ECM, such as heparin sulfate and elastin, thereby
attenuating lung inﬂammatory response and emphysema [43]. There-
fore, the development of pharmacological mimetics to replenish/
augment SOD3 speciﬁcally in the lung (matrix) may have a thera-
peutic potential in the intervention of COPD/emphysema. Further-
more, SOD3 therapy can be combined with other therapeutic
approaches in management of COPD.
5.2. Glutathione peroxidase (GPx) mimetic
Ebselen, a selenium-based organic complex, has been found to
mimic the activity of glutathione peroxidase (GPx). Since ebselen
can also increase the efﬁciency of GSH, it can thus be used as therapy
against oxidative stress and inﬂammation. Ebselen possesses strong
antioxidant activity and has been reported to have a strong neutraliz-
ing effect against peroxynitrite radical [48]. In human leukocytes ex-
posed to peroxynitrite, ebselen was found to inhibit the activation
of NF-κB/AP-1 and expression of pro-inﬂammatory genes expression.
In vivo activity of ebselen has been demonstrated by virtue of its abil-
ity to prevent LPS-induced airway inﬂammation [49,50]. However, its
protective effect against cigarette smoke induced lung inﬂammation
is yet to be reported. BXT-51072 and BXT-51077, which are low mo-
lecular weight, orally active organoselenium GPx mimetic have
shown to possess the peroxide neutralizing capabilities and regulate
inﬂammation by preventing the activation of inﬂammatory mediators
[51]. The mechanism underlying these protective effects is thought to
be via inhibition of transcription of the inﬂammatory mediators.
5.3. Peroxynitrite decomposition catalysts
Peroxynitrite decomposition catalysts, unlike other enzyme mi-
metics, possess catalytic activity against peroxynitrite. They are iron
containing porphyrin complexes and are similar in structure to
AEOL10150 and AEOL10113. In neonatal rat intestinal ischemic-
reperfusion model, administration of FeTMPyP, a peroxynitrite
decomposition catalyst, provided limited protection by reducing
P-selectin expression, systemic NO production, neutrophil inﬁltration
in ileum and lipid peroxidation in both lungs and ileum; and pre-
served intestinal antioxidant capacity [52]. Another peroxynitrite
decomposition catalyst, FP15, decreased ischemic injury in rats and
improved cardiac function and survival of mice in a chronic model
of doxorubicin-induced cardiotoxicity [53]. The efﬁcacy of peroxyni-
trite decomposition catalysts has been reported in vivo in various
animal models of disease associated with peroxynitrite generation
[54]. However, it remains to be seen whether or not this class of anti-
oxidants is also effective in a smoking model for COPD associated
with high levels of peroxynitrite generation.
5.4. Spin traps
Spin traps are chemical agents, which can quench free radicals
and are as such used experimentally for studying reactions involving
free radicals. On trapping free radicals, spin traps form a stable
end product suitable for measurement. Most spin traps have a
nitrone- or nitroxide-nucleus and are derivatives of these moieties.
Although spin traps have been extensively used for in vitro studies,
their therapeutic in vivo effects have also been investigated in inﬂam-
mation using α-phenyl-N-tert-butyl nitrone [55]. One of the difﬁcul-
ties of studying with earlier spin traps was their extremely small
half lives and their generation of dangerous •OH on decay. This disad-
vantage has however, been overcome by introduction of electronwithdrawing moieties around the core pyrroline ring [56]. Spin
traps containing nitrone- core have been shown to possess strong an-
tioxidant properties, and their therapeutic effects have been investi-
gated in Alzheimer's and Parkinson's diseases [57]. Isoindole-based
nitrones [58] and azulenyl-based nitrones [59] are already in vogue
and one such agent STANZ has been reported to have strong antioxi-
dant properties and can inhibit lipid peroxidation in vitro. A phenyl-
based nitrone spin trap NXY-059 has been tested in acute ischemic
stroke. These compounds have also been shown to impart therapeutic
beneﬁts in a number of animal models of lung disease. Recent studies
have suggested that inhibition of NO generation via iNOS inhibition
by various chemical inhibitors [N(6)-(1-iminoethyl)-L-lysine (L-
NIL), G-nitro-L-arginine-methyl ester or L-NAME or using the knock-
out mouse model resulted in attenuation of emphysema [60,61]. This
effect may be due to the removal of NO so that ONOO will not be
formed. It is possible that selective inhibition of iNOS, along with
the supplementation of other antioxidants, may provide a strategy
in management of severe COPD. Further investigations are required
to develop these compounds (spin traps and iNOS) for long-term
use in cigarette smoke/oxidative stress mediated chronic lung dis-
eases including COPD.
5.5. Nrf2 activators
Nuclear factor erythroid 2 p45-related factor 2 (Nrf2) is a basic-
leucine zipper (b-ZIP) transcription factor present in the cytoplasm
[62]. It plays a pivotal role in cellular defense against electrophiles
and ROS present in cigarette smoke. In response to various factors,
such as oxidative, carbonyl and electrophilic stresses, Nrf2 detaches
from its cytosolic inhibitor, Kelch-like ECH-associated protein 1
(Keap1), and translocates into the nucleus. Upon entering in the
nucleus, Nrf2 binds to ARE of target genes along with other binding
factors and cofactors leading to an induction of stress response
genes [63–65]. Most of the antioxidants and phase II cytoprotective
genes, such as heme oxygenase-1 (HO-1), NAD(P)H/quinone oxido-
reductase 1 (NQO1), glutamate-cysteine ligase, glutamyl cysteine
synthase, glutathione peroxidase, and several members of the gluta-
thione S-transferase family are regulated by Nrf2 [62,66,67].
Studies have also shown increased susceptibility of Nrf2 null mice
to cigarette smoke-induced emphysema compared with wild-type
mice [68,69], suggesting the protective role of Nrf2. Furthermore,
Nrf2 appears to protect against pulmonary hyperoxia/bleomycin
injury and ovalbumin challenge in mice, presumably by upregulating
the transcription of lung antioxidant defense enzymes. It has been
shown that reduction of Nrf2 protein levels in pulmonary macro-
phages, and in lungs of patients with COPD occurs via loss of Nrf2
positive regulator DJ-1, and posttranslational modiﬁcations of the
Keap1–Bach1 equilibrium [70–72]. There is a possibility that poly-
morphisms in the promoter regions of Nrf2-Keap1 pathway genes
may affect the phenotype in COPD. The levels of Nrf2 protein are de-
creased in lungs of patients with COPD, and this decrease was associ-
ated with reduction/oxidative posttranslational modiﬁcations and
degradation of histone deacetylase 2 (HDAC2) [73,74].
HDAC2 is known to be post-translationally modiﬁed by carbonyla-
tion and S-nitrosylation on cysteine residues [75–78]. S-nitrosylation
of HDAC2 is known to occur at Cys 262 and Cys 274 which does
not affect its deacetylase activity [79]. A recent study has shown
that in alveolar macrophages obtained from patients with COPD,
S-nitrosylation of HDAC2 at Cys-262 and Cys-274 is increased, and
this modiﬁcation abolishes its GR-transrepression activity, and
renders corticosteroid insensitive for its efﬁcacy [80]. Furthermore,
activation of Nrf2 by sulforaphane denitrosylates HDAC2, and subse-
quently restores dexamethasone sensitivity in alveolar macrophages.
It is also known that HDACs inactivation by oxidative/carbonyl stress
may antagonize deacetylase activity [81]. Aldehydes, such as 4-HNE
and acrolein alkylate (carbonylate) HDAC2 by covalent modiﬁcation
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Cys(273) [81]. Hence, it remains to be seen whether S-nitrosylation
and thiol alkylation, which occurs on these cysteine residues would
also be reversed by Nrf2 activation, though oxidative/nitrosative
posttranslational of HDAC2 is subject to ubiquitination, and proteo-
somal degradation [77]. Furthermore, Nrf2 and HDAC2 both are car-
bonylated in response to CS and in patients with COPD. These dual
modiﬁcations on each molecule (cysteine residues) may cause spe-
ciﬁc steric hindrance and post-translational modiﬁcations can lead
to proteosomal degradation. Nevertheless, it may be possible to re-
verse the carbonylation and S-nitrosylation of HDAC2 by pharmaco-
logical means (via activation of thioredoxin reductase and carbonyl/
aldehyde reductases) so that they can function effectively in early
stages of COPD and overcome steroid resistance.
Compounds, which are potent activators of Nrf2, may buffer the
antioxidant potential in the lung against cigarette smoke, particularly
in patients with COPD, can thus be developed for their therapeutic ap-
plication. Alternatively, novel compounds which are potent activators
of Nrf2 or which stabilize Keap1/DJ-1/Maf proteins can be developed.
Therapeutically, it has been shown that activating Nrf2 with the com-
pound 1[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole
(CDDO)-imidazolide can reduce CS- and LPS-induced inﬂammation
providing a novel therapeutic strategy for COPD [65,82]. Such com-
pounds will augment the antioxidant potential in the lung against
cigarette smoke, particularly in patients with COPD. Furthermore, it
may be possible to combine the strategy of Nrf2 activators with
other currently available therapeutic options (e.g. phosphodiesterase
4 inhibitors, bronchodilators, and steroids) in management of COPD.
However, one has to keep in mind whether there is a polymorphisms
in the promoter regions of Nrf2 gene and its pathway genes in sus-
ceptible smokers and patients with COPD.
Various small molecule activators of Nrf2 signaling are currently
being investigated for their anticancer and anti-inﬂammatory proper-
ties (both lung cancer and COPD are associated to cigarette/tobacco
smoke exposure). A wide variety of dietary and synthetic compounds
that function as potent inducers of ARE-regulated gene expression
have been shown to exert chemopreventive activities, e.g., various di-
etary and synthetic compounds, such as sulforaphane [82], dithio-
lethione [83], curcumin and caffeic acid phenethyl ester (CAPE) [84]
have been reported as potent inducers of ARE regulated genes.
Chalcones or chalconoids (1,3-diphenyl-2-propen-1-ones) and
Michael acceptors are important groups of naturally occurring com-
pounds of antioxidant and chemoprotective agents [85]. Chalcones
have been found to have relevant physiological properties, due to
their ability to bind to proteins related to cell apoptosis and prolifer-
ation [86]. Recently, it has been reported that chalcones can impart
anti-inﬂammatory effects due to the inhibition of the NF-κB pathway
[87,88]. Furthermore, chalcones have also been reported to activate
Nrf2/ARE pathway, thus inducing phase II detoxifying enzyme ex-
pression [89]. Currently, various derivatives of chalcones are being
developed for improving the antioxidant and anti-inﬂammatory
properties of chalcones, which may ﬁnd potential therapeutic role
in COPD [62].
6. Redox sensors: enzymatic and non-enzymatic
The intracellular redox state is a dynamic system and is constantly
inﬂuenced by the energy status of the cell. Various external and inter-
nal factors can alter the redox state of the cell. The most common
redox sensors of the cell include the NADP/NADPH, NAD+/NADH,
and glutathione systems (GSH/GSSG). Since the relative concentra-
tions of the reduced versus oxidized components of these redox cou-
ples determine the overall redox state of the cell, the effect of any
external oxidative stress is detected by these redox sensors. While
GSH is the most abundant cytosolic thiol redox sensor, the NADP/
NADPH system acts as a buffer against mitochondrial redox shifts. Inaddition, NADP/NADPH is associated as a cofactor with several enzy-
matic reactions and with lipid metabolism.
6.1. Thioredoxin
Thioredoxin (Trx) and redox effector factor-1 (Ref-1) belong to
oxidoreductase family of redox sensors. During oxidative stress, Trx,
which is bound to proteins, such as hepatopoietin [90] and the apo-
ptosis signal regulating kinase (ASK-1) [91], as heterodimeric com-
plexes are released from these complexes liberating the proteins
[90]. This leads to the multimerization of ASK-1 and dimerization of
hepatopoietin. In the dissociated form, Trx reduces a key thiol group
within cys62 of the p65/NF-κB subunit in the nucleus leading to tran-
scriptional activation [92]. Concomitantly, the prevailing oxidative
stress activates free ASK-1, leading to the activation of the pro-
inﬂammatory p38MAPK and JNK pathways [3–5,20]. The two path-
ways discussed above are redox sensitive, which is supported by the
observation, wherein inhibition of Trx (may lead to reducing environ-
ment in the nucleus) with MOL-294 (a small molecular weight inhib-
itor of Trx), blocks activation of both pro-inﬂammatory NF-κB and
AP-1-dependent transcription. Inhibition of NF-κB activation by
MOL-294, is also accompanied by diminished neutrophil inﬂux and
TNF-α production [93]. Similarly, Ref-1, another redox sensor, on in-
hibition by PNRI-299, leads to the inactivation of AP-1 pathway [94].
Furthermore, in vivo administrations of both MOL-294 and PNRI-299
in a murine ovalbumin challenge model of asthma have been shown
to reduce various clinical parameters [94,95]. On the contrary to
above ﬁndings, Trx, overexpression of Trx-1 or treatment of mice
with recombinant human Trx attenuates cigarette smoke-mediated
oxidative stress and pulmonary emphysema [96]. This may be due
to its direct intra- or extracellular antioxidant property rather than
its nuclear effect. However, this molecular effect in cigarette smoke-
mediated lung damage, inﬂammatory response, and in pathogenesis
of COPD remains to be investigated.
A family of tri- and tetra-oligopeptides derived from the canonical
CxxC motif of the Trx active site and a modiﬁed CxC motif has been
recently synthesized [97]. These constitute the Trx-mimetic com-
pounds, which are N- and C-terminal-blocked peptides that consist
of two cysteine residues that ﬂank the two-amino-acid CxxC motif
(CB4 and CB6) or the single-amino-acid CxC motif (CB3). These Trx-
mimetics have been reported to upregulate various redox sensitive
processes in the cell [97]. Thus, upregulation of Trx by various syn-
thetic small molecules may be an important strategy employed
against oxidative stress and abnormal inﬂammatory responses occur-
ing in patients with COPD.
6.2. Peroxiredoxins
Peroxiredoxins (Prdx), are members of a superfamily of selenium-
independent peroxidases. Prdx exerts a protective role through per-
oxidase activity against H2O2, peroxynitrite and phospholipid hydro-
peroxides [98,99]. Depending on the number of active Cys residues,
mammalian Prdx falls into typical double-cysteine (Prdx1-Prdx4),
atypical double-cysteine (Prdx5), and single-cysteine (Prdx6) classes.
Prdx6 is highly expressed in the lung tissue, alveolar epithelial type II
cells, bronchial Clara cells, and alveolar macrophages [100,101].
Prdx6 protects against oxidative stress–induced lipid peroxidation
and apoptosis and regulate cellular signaling [102]. Therefore, it ap-
pears that Prdx6 is an important protective enzyme that counteracts
oxidant stress in the lung. The important protective role of Prdx
in defense against oxidative stress was demonstrated in a study
involving PRDX1 gene knockout mice [103]. In another study, it
was hypothesized that targeted disruption of PRDX6 would lead
to enhanced susceptibility to cigarette smoke (CS)-mediated lung
inﬂammation and/or emphysema in mouse lungs [104]. However,
this study revealed that targeted disruption of Prdx6 did not
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Fig. 2. Chemical structures of thiol antioxidants.
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tioxidants, suggesting a critical role of lung Prdx6 and several com-
pensatory antioxidant mechanisms during acute CS-induced
adaptive response. Furthermore, it was found that the protective
effect of Prdx6 was lost in chronic CS exposure leading to pulmo-
nary emphysema [104]. Prdx acts as a substrate for sulﬁredoxins
(Nrf2-dependent), another enzyme important in redox antioxidant
pathways. Strategies to increase the expression of Prdx or pharma-
cological ampliﬁcation by small molecules may, therefore, be ben-
eﬁcial in the treatment of COPD.
6.3. Glutaredoxin
Glutaredoxins (Glrx) are thiol disulﬁde oxido-reductases, which
possess antioxidant and catalytic functions closely associated with
GSH. Glrx1 is a potential redox modulatory protein regulating the in-
tracellular, as well as extracellular homeostasis of glutathionylated
proteins and GSH in human lung. Glrx1 is implicated in regulation
of pro-inﬂammatory NF-κB signaling and chromatin modiﬁcations
[105,106]. In a cross-sectional study, it has been demonstrated that
Glrx1 was mainly expressed in alveolar macrophages, extracellular
ﬂuids and sputum supernatants, and the levels of this enzyme were
decreased in COPD patients [107]. Glrx1 mRNA and protein expres-
sion was decreased in alveolar epithelial cells exposed to CS along
with decreased activity and increased protein S-glutathionylation
[108]. In the same study, irreversible oxidation and carbonylation of
recombinant Glrx1 by CS and acrolein was also demonstrated,
which was associated with its reduced enzyme activity. Interestingly,
overexpression of Glrx1 attenuated protein S-glutathionylation in-
duced by CS and increased cell survival [108]. Tracheal epithelial
cells of mice deﬁcient in Glrx1 were found to be more sensitive to
CS-induced cell death with corresponding increases in protein S-
glutathionylation [108]. Thus, CS can modulate Glrx1 at both the
gene expression level and also by modifying Glrx1 enzyme activity.
A recent study has shown that Glrx1 regulates cigarette smoke-
mediated lung inﬂammation via S-glutathionylation and differential
modulation of IκB-kinases in mice [105]. Hence, pharmacological
intervention or strategies to increase Glrx1 gene expression and mod-
ulate its enzyme activity would have potential in the regulation of
cigarette smoke-mediated lung inﬂammation in COPD.
7. Small molecule thiol antioxidants
7.1. N-acetyl-L-cysteine (NAC)
NAC is an acetyl derivative of the amino acid, cysteine, and is a
strong reducing agent (Fig. 2). NAC has been used as a mucolytic
agent and reduces mucus viscosity, thereby improving muco-cilliary
clearance. In the gastrointestinal tract, NAC is deacetylated into cyste-
ine and also serves as precursor of GSH in the cells. Its ability to re-
duce disulﬁde bond makes it a good reducing agent and also allows
it to neutralize oxidant species. Within the cells, NAC reduces cystine
into cysteine, and may thus serve as an important mechanism for
elevation of intracellular GSH in vivo in lungs. Oral NAC attenuates
elastase-induced pulmonary emphysema in rats implicating its possi-
ble role in the management of emphysema/COPD [109].
Clinical studies regarding the beneﬁcial effects of NAC and other
thiols in patients with COPD has yielded mixed results (Table 3)
[110–129]. While a Cochrane systematic review showed a signiﬁcant
reduction of 0.79 exacerbations per patient per year compared with
placebo, a 29% decrease in number of exacerbations, whereas small-
scale trials failed to demonstrate any clear clinical beneﬁts [113].
However, a few meta-analyses have shown a small, but signiﬁcant
clinical beneﬁt in patients with COPD [115,123].
Considering that GSH plays an important role in the control of
oxidative/carbonyl stress in COPD, NAC has mainly been used,although with varying success, to enhance lung GSH in patients
with COPD [116]. A randomized, double-blind, placebo controlled
phase II trial, with a 6-month oral dose of 600 mg NAC, twice daily,
was found to signiﬁcantly reduce various plasma and BAL ﬂuid oxida-
tive biomarkers in smokers [124]. Another study involving oral ad-
ministration of NAC (600 mg twice daily for 2 months) was shown
to rapidly reduce oxidant load in the airways of stable COPD patients
[120], and was associated with a reduction in bronchial mucus hyper-
secretion and a decline in FEV1, and COPD exacerbations [114].
NAC has a beneﬁcial effect on systemic oxidative stress, as oral ad-
ministration of NAC was found to increase the quadriceps endurance
time of severe COPD patients [125]. In contrast, another multicenter
study using NAC delivered by metered-dose inhalers in patients
with chronic cough did not show any beneﬁcial effect on well-
being, sensation of dyspnea, cough, or lung function [126]. Although
there is a body of evidence suggesting beneﬁcial effects of NAC in
COPD patients, it is not clear whether NAC is used as a mere mainte-
nance therapy [127]. However, a phase III multicenter trial, Bronchitis
Randomized on NAC Cost-Utility Study (BRONCUS), has supported
this notion [111]. Although the BRONCUS study showed no effect on
decline in FEV1, a reduction in overinﬂation and exacerbation in pa-
tients with severe COPD not treated with inhaled glucocorticoids
was observed [111]. In a recent study, using an infection model of
A549 alveolar epithelial cells infected with the inﬂuenza virus, NAC
was found to inhibit induction of MUC5AC, interleukin (IL)-8, IL-6,
and TNF-alpha [128]. NAC was also shown to inhibit the replication
of the inﬂuenza virus in the same study.
In view of the above, and due to conﬂicting reports on the beneﬁ-
cial effects of NAC, further studies are required using NAC at higher
doses (1200 or 1800 mg/day, or even higher doses) or by using
other thiol agents with greater bioavailability in order to observe
any clinical beneﬁts on lung function, reduced exacerbation rate,
and improved health status/quality of life. Overall, NAC can be per-
ceived to play a therapeutic role in the management of COPD, due
to its ability to increase intracellular GSH, along with its knownmuco-
lytic properties. Therefore, NAC may be more likely to be of beneﬁt in
subjects with mucus hypersecretion and in other COPD phenotypes,
which requires further clinical studies regarding NAC as a therapeutic
alternative against COPD and its pulmonary emphysema phenotype.
7.2. N-acystelyn (NAL)
NAL, a lysine salt of NAC, is also a mucolytic and antioxidant
(reducing) thiol compound (Fig. 2). While NAC is acidic in solution,
NAL has a neutral pH in solution and can be aerosolized into the
Table 3
Clinical trials conducted for the efﬁcacy of thiol antioxidants in smokers and COPD.
Clinical Trial Antioxidant Study Aim Outcome References
BRONCUS NAC Effect of NAC on FEV1 No effect. No change on decline in FEV1 [110,111]
A reduction in lung overinﬂation in patients with
severe COPD without inhaled glucocorticoids.
Decrease of exacerbation if NAC and Inhaled
corticosteroids combined.
Systematic Cochrane review of 23
randomized, controlled trails
NAC
(2 months of oral therapy)
Effect of NAC and antibiotics on
number of days of disability
No difference in lung function. Signiﬁcant reduction
in days of disability (0.65 day per patient per
month) and 29% reduction in exacerbations.
[112,113]
Systematic Cochrane review of
randomized, controlled trials;
11 of 39 retrieved trials
NAC Use of validated score to evaluate
the quality of each study
9 trials showed prevention of exacerbation and 5 of
which addressed improvement of symptoms
compared with 34.6% of patients receiving placebo
[114]
Meta-analysis of published trials NAC Assess possible prophylactic
beneﬁts of prolonged treatment
23% decrease in number of acute exacerbations [115]
- NAC (600 mg/d, 5 days and
600 mg, 3/d. 5 days)
Effect of NAC on GSH and cysteine Increase of GSH at day 5 and cysteine (plasma) at
day 5
[116]
- NAC (600 mg once a day
for 12 months)
Effect of NAC on H2O2 and TBARS
in EBC
No change in TBARS levels [117]
Reduce H2O2 levels
- NAC (600 mg/d, 7 days) Effect of NAC on FEV1,
breathlessness
No difference compared to placebo group [118]
- NAC (600 mg /d) Effect of NAC on cytokine and
exhaled breath condensate (ECD)
Decrease IL-8 and ECP level in NAC group [119]
- NAC (600mg × 2/d × 2months) Effect of NAC on H2O2 Decrease H2O2 level in NAC group [120]
EQUALIFE studies Erdosteine-thiol compound,
300 mg b.i.d for months
Effect on exacerbation rate,
hospitalization, lung function and
quality of life
Decreased exacerbations and fewer days in
hospital. No loss of lung function and improvement
in health-related quality of life
[121]
- Erdosteine 300 mg twice a
day for 7–10 days
Effect on COPD symptoms during
exacerbations and hospitalization
days
Improvement of symptoms and reduced time of
disease in patients with acute exacerbation of
chronic bronchitis and COPD
[136,137]
Erdosteine 600 mg/day Effect on oxidative stress and
inﬂammation
Reduced ROS levels in peripheral blood of stable
COPD patients who are current smokers, together
with reduction in levels of IL-6 and IL-8 in bronchial
secretions
[138,139]
Small scale UK studies Carbocysteine Effect of 2.25–3.00 g
carbocysteine daily along with
placebo in chronic bronchitis
Heterogeneous results on alterations in FEV1, peak
ﬂow rate and dyspnea scores
[148–151]
An Italian multi-center,
prospective, double-blind RCT
involving 662 outpatients
with a chronic bronchitis
Carbocysteine Effect of 2.7 g S-CMC-Lys once
daily for 6 months on COPD
patients
No signiﬁcant difference in baseline FEV1 between
the groups. Mean time to ﬁrst exacerbation was
signiﬁcantly prolonged and signiﬁcant reduction in
mean days of acute respiratory illness per patient.
[152]
A double–blind, parallel-group
study in the UK in 109 patients
with chronic bronchitis over
6 winter months
Carbocysteine Effect of 750 mg carbocysteine
three times daily compared with
placebo on peak ﬂow and
exacerbation rate.
No signiﬁcant difference in exacerbation rate.
Signiﬁcant increases in peak ﬂow from baseline in
both placebo and intervention groups
[153]
RCTs in Tokyo in 156 patients with
COPD over a 12-month period
Carbocysteine Effect of 1.5 g carbocysteine daily
with placebo
No signiﬁcant differences in severity of COPD.
Signiﬁcant reduction in the number of common
colds and reduction in rate of exacerbation
[154,155]
RCTs in Japan involving 142
patients with COPD conducted
over a 12-month period
Carbocysteine Treatement with 500 mg
carbocysteine three times a day
Consistent reduction in exacerbation frequency. No
change in lung function
[147]
PEACE study Carbocysteine (carbocisteine) Effect on rate of exacerbations Long-term (one year) use of carbocysteine
(1500 mg/day) produced reduction in numbers of
exacerbations in patients with COPD
[122]
BRONCUS=Bronchitis Randomized on N-acetyl-L-cysteine Cost Utility Study, bid=Twice daily; FEV1=Forced expiratory volume in 1 second, TBARS=Thiobarbituric acid reactive
substances, NAC=N-acetyl-L-cysteine, EBC=Exhaled Breath Condensate, ECP: eosinophilic cationic protein, RCT: Randomized placebo-controlled trials.
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involving NAL and NAC, it was found that both of the compounds en-
hanced intracellular GSH in lung alveolar epithelial cells and inhibited
the release of H2O2 and O2•– from human blood-derived polymorpho-
nuclear leukocytes in smokers and patients with COPD [129]. This
study also revealed that NAL could inhibit ROS generation by
serum-opsonized zymosan stimulated human polymorphonuclear
neutrophils in a fashion similar to NAC. NAL could also act as an
anti-inﬂammatory agent, as shown in a study where NAL was
shown to inhibit oxidant-mediated IL-8 release in monocytes. There-
fore, NAL is an antioxidant and anti-inﬂammatory agent, which may
have a potential therapeutic beneﬁt for COPD treatment. Its ability
to be aerosolized adds to its therapeutic advantage. For example,
the lung deposition of NAL was shown to be effective, when given
via a metered dose inhaler formulation in healthy subjects [130].Beﬁtting from its therapeutic advantage, a clinical trial using NAL
for treatment of COPD is needed.
7.3. Procysteine and GSH-esters
Procysteine (L-2-oxothiazolidine-4-carboxylate or cysteine l-2-
oxothiazolidine-4-carboxylic acid) is a cysteine-relieving compound
that increases the intracellular cysteine levels, and has greater bio-
availability than NAC. This thiol compound is well-tolerated and has
been shown to increase mitochondrial levels of GSH in alveolar type
II cells [131]. A recent study by Hodge et al. showed that cigarette
smoke-induced changes to alveolar macrophage phenotype activated
M1 (proinﬂammatory; regulation of antigen presentation) or alterna-
tively activated M2 (poor antigen presentation; improved efferocyto-
sis) markers and function (efferocytosis and proinﬂammatory
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mouse lung. It is concluded that the increased efferocytosis and avail-
ability of GSH in response to procysteine may be useful as adjunct
therapy for improving macrophage function in COPD and in suscepti-
ble smokers [132].
Glutathione esters, particularly GSH monoethyl esters, can in-
crease the GSH levels of the cells by cleavage of ester bond (an ethyl
group esteriﬁed to glycine). GSH esters have been shown to increase
GSH levels in the lungs of rats and in vitro in epithelial cells; however,
this compound can be cytotoxic, and variation in the uptake levels of
GSH has been shown in various cellular models [133]. Furthermore, it
may be cautious to note that therapeutic strategies involving GSH or
its analogs or thiol compounds must be carefully designed keeping
in mind the species barrier, bioavailability, half-life of the analogs,
and generation of toxic byproducts by the analogues, as well as inter-
ference with metabolic and signaling pathways in a cell or tissue. One
such alternative for GSH drug delivery will be via nanomedicine/
liposome-encapsulated form.
7.4. N-isobutyrylcysteine (NIC)
One of the disadvantages of using NAC is its low bioavailability,
due to its greater ﬁrst pass hydrolysis in biological systems. Therefore,
a drug having similar effects as NAC, but with greater bioavailability,
might prove to be a more effective treatment for chronic bronchitis/
COPD. One such compound is NIC, which is also a thiol molecule
with lesser ﬁrst pass hydrolysis and bioavailability as high as 80%
compared to NAC [134]. However, therapeutic evaluations of NIC
against exacerbations in chronic bronchitis have revealed that NIC
did not do better than the placebo [134]. A similar non-effective result
was reported in patients with acute exacerbations of COPD [134].
7.5. Erdosteine
Erdosteine is a thiol antioxidant having mucoactive properties
(Fig. 2), and the ability to reduce bacterial adhesiveness. This com-
pound was introduced as a mucolytic agent for the treatment of
chronic pulmonary diseases. Erdosteine breaks the disulﬁde bonds of
mucus glycoproteins, affecting the physical properties of the mucus,
thus leading to increased cough clearance [135]. In addition, erdos-
teine has been reported to have antioxidant, anti-inﬂammatory, and
antibacterial activity.
In a randomized, placebo-controlled clinical study, ‘Equalife’ in-
volving oral administration of 300 mg erdosteine twice daily for
8 months showed signiﬁcant reduction in exacerbations compared
to the placebo group [121]. The same study also demonstrated that
patients receiving erdosteine showed signiﬁcant improvements in
their quality of health without any adverse effect on lung function.
In another clinical study involving administration of erdosteine
300 mg twice a day for 7–10 days improved the symptoms and re-
duced the length of time for the disease in patients with acute exac-
erbation of chronic bronchitis and COPD [136]. Long-term treatment
of stable COPD patients with erdosteine reduced the rate of hospital-
ization and acute exacerbation. Furthermore, erdosteine has been
reported to impart health beneﬁts in patients suffering from repeat-
ed, prolonged or severe exacerbations of COPD [136,137]. Dal Negro
et al. showed that erdosteine at a dose of 600 mg/day proved effective
in signiﬁcantly reducing ROS levels in peripheral blood of stable COPD
patients who are current smokers, together with reduction in levels
of some chemotactic proinﬂammatory cytokines (IL-6 and IL-8) in
their bronchial secretions [138]. Recently, the anti-inﬂammatory
properties of erdosteine were conﬁrmed in a study involving COPD
subjects, wherein by its ability to reduce the proinﬂammatory eicosa-
noids levels [139]. Hence, this compound may be a choice as another
antioxidant and mucolytic agent in management of COPD.7.6. Carbocysteine
S-carboxymethylcysteine (carbocysteine or S-CMC) is a blocked
thiol derivative of amino-acid; L-cysteine (2). Oral preparations
of carbocysteine both as S-CMC and its lysine salt (S-CMC-lys) are
available. The lysine salt is activated in the gastrointestinal tract
post-cleavage of the lysine residue to yield the active drug S-CMC.
Carbocysteine is a muco-active drug with reported in vitro free radical
scavenging and anti-inﬂammatory properties. While mucolytic drugs,
such as NAC and erdosteine bear free sulphydryl (thiol) groups,
through which they split glycoprotein bonds in mucous, carbocys-
teine differs in structure and mechanism of action from other
commonly available mucolytics. The mucus produced under the inﬂu-
ence of carbocysteine, has increased sialomucin content. Sialomucins
inﬂuence the rheological properties of mucus via the inhibition of
kinins, thereby reducing or preventing bronchial inﬂammation and
bronchospasm [140].
In COPD patients treated with S-CMC-Lys for a 6-month period,
Carpagnano et al. demonstrated a signiﬁcant reduction in exhaled 8-
isoprostane and pro-inﬂammatory cytokine: IL-6, providing an in
vivo support for the spate of in vitro evidences, proving that the
drug has anti-inﬂammatory and antioxidant properties [141].
Furthermore, anti-inﬂammatory action of carbocysteine has been
well documented in models of pulmonary inﬂammation involving
several different cytokine proﬁles and it has been shown to protect
against emphysema induced by cigarette smoke in rats [142]. In
carrageenan-induced pleurisy, oral administration of S-CMC-lys
has been shown to attenuate neutrophil recruitment in acute IL-1β-
induced airway inﬂammation and neutrophil, macrophage and
eosinophil migration into the pleural space [143]. Carbocysteine-
mediated attenuation of mucus glycoproteins hypersecretion and re-
duced inﬂammatory cells, free radical and elastase activity in the
bronchoalveolar lavage ﬂuid of rats with sulfur dioxide-induced air-
way inﬂammation have been reported [144].
Carbocysteine is shown to enhance both in vivo and in vitromuco-
ciliary clearance velocity, particularly in patients with chronic
bronchitis with slow clearance before treatment [140]. Since carbo-
cysteine has the potential to reduce bacterial respiratory tract infec-
tions in COPD, it has been suggested that it may act through the
inhibition of pathogen adherence to cells. In vitro studies involving
treatment with carbocysteine have demonstrated a signiﬁcant reduc-
tion in adherence ofMoraxella catarrhalis (this bacteria causes exacer-
bations of COPD) to the pharyngeal epithelial cells, of both healthy
subjects and those with chronic bronchitis, when compared to place-
bo treated group [145]. This observation has been further corroborated
by a similar observation that, carbocysteine signiﬁcantly reduced at-
tachment of Streptococcus pneumoniae to pharyngeal epithelial cells
taken from healthy subjects by direct in vitro treatment of the cells
with the drug [146]. Reduction in frequency of common colds
including infections and associated exacerbations in COPD patients on
treatment with carbocysteine have been attributed to its ability to de-
crease ICAM-1 expression in the respiratory tract [147].
There are reports regarding the clinical use of carbocysteine to
treat COPD patients with mixed results on alterations in lung function
and exacerbation rate (Table 3) [122,147–155]. Importantly, the
PEACE study involving 709 Chinese COPD subjects, has examined
the effect of over three year period of treatment with carbocysteine
(250 mg t.d.s) focusing on the rate of COPD exacerbations. This
study has revealed that COPD patients whom were treated with car-
bocysteine experienced fewer numbers of exacerbations per year
[122]. Although very few side effects have been reported for carbo-
cysteine, over-dosage may cause mild side-effects, such as gastric dis-
comfort. More systematic studies and understanding the detailed
mechanism of action of carbocysteine may uphold the candidature
of carbocysteine as a major therapeutic agent for treatment of respi-
ratory diseases including COPD. Furthermore, a longer use of
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tions in patients with COPD. Overall, clinical studies have revealed
that carbocysteine is well-tolerated, has mucoactive properties (mu-
colytic) and can also reduce bacterial adhesiveness. Currently, carbo-
cysteine is considered to be a useful muco-regulatory agent for the
treatment of COPD that provides symptomatic relief to some patients,
along with resolute sputum production, and may reduce exacerbation
rates. Carbocystine may be choice as compared to NAC, or other avail-
able thiols in management of COPD and its exacerbations.
7.7. Fudosteine
Fudosteine, [(−)-(R)-2-amino-3-(3-hydroxypropylthio)] propio-
nic acid (Fig. 2), has been used in the treatment of chronic respiratory
diseases, such as bronchial asthma, chronic bronchitis, pulmonary
emphysema, COPD, and bronchiectasis as a mucoactive agent
[156,157]. Fudosteine acts by increasing cysteine levels of the cells
and has greater bioavailability than NAC. Fudosteine downregulates
MUC5AC gene expression thus inhibits mucin hypersecretion [156].
Although, little is known about its mode of action, fudosteine has
shown some promising potential in treatment of patients with
COPD [158]. These ﬁndings suggest that fudosteine may be useful in
controlling oxidative/carbonyl stress-related mucus secretion states
in patients with asthma, bronchiectasis or COPD. Fudosteine
(500 mg/kg, p.o.) signiﬁcantly augmented the output volume of re-
spiratory tract ﬂuid in rabbits and increased chloride ion concentra-
tion in bronchoalveolar lavage of rats [159]. Fudosteine also reduced
the activation of p38 MAPK and ERK pathways [156]. Fudosteine has
also been shown to inhibit peroxynitrite-induced cellular alterations
in lung by direct scavenging of this free radical [160]. Further studies
are required clinical efﬁcacy of fudosteine in treatment of COPD.
7.8. Ergothioneine
Ergothioneine (2-mercaptohistidine trimethylbetaine) is a naturally
occurring antioxidant found in most plants and animal tissues (Fig. 2)
[161]. Chemically, L-ergothioneine corresponds to the betaine of 2-
thio-L-histidine. In aqueous solution, the tautomeric-2-thio-imidazole
exists predominantly in the thione form. The compound is known to
be formed via hercynine from histidine, methionine, and cysteine in
microorganisms. Ergothioneine inhibits the peroxynitrite-dependent
nitration of nitrotyrosine [162], and also inhibits oxidative DNA repair
and cell death [163]. Ergothioneine also inhibits the formation of xan-
thine and hypoxanthine (a precursor of xanthine), which are shown to
be activated in patients with COPD [4,5]. The role of ergothioneine on
S-nitrosoglutathione catabolism and generation of vasodilatory NO has
been shown [164].
Interestingly, ergothioneine increases cellular tolerance/availability
of NAC. The role of ergothioneine in inhibition of oxidative stress-
mediated signal transduction mechanisms involved in cellular
inﬂammatory responses has been shown in lung epithelial cells.
Ergothioneine inhibits oxidative stress- and TNF-α-induced NF-κB
activation and IL-8 release in alveolar epithelial cells [165]. Thus,
ergothioneine may be a potential antioxidant/anti-inﬂammatory
agent to inhibit the chronic inﬂammatory response, which occurs in
the development of chronic inﬂammatory lung diseases including
COPD. However, no documented evidence are available to attest this
in management of COPD.
8. Lipid peroxidation and protein carbonylation
inhibitors/blockers
8.1. Edaravone (MC-186)
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a widely
acclaimed and potent free-radical scavenger and exhibits itsantioxidant ability by inhibiting lipid peroxidation [166,167]. Inter-
estingly, edavarone can also inhibit protein carbonylation by direct
carbonyl-scavenging mechanism [168]. Protein carbonylation and
carbonyl stress via aldehydes and formation of advanced glycation
end-products occur in several pulmonary diseases including COPD,
and hence it may be the direct target for prevention strategies
[2,17,169,170]. Since edaravone has protective effects on both hemi-
spheric embolization and transient cerebral ischemia, it has therefore,
been clinically tested to treat acute brain infarction in Japan
[171–173]. In a study in rat model of ischemia/reperfusion injury,
Ito et al. [174], has demonstrated that edaravone ameliorated the
lung injury induced by intestinal ischemia/reperfusion. In the same
study [174], edaravone was found to decrease inﬁltration of neutro-
phils, membrane lipid peroxidation and downregulate expression of
IL-6 mRNA in the lungs, leading to a signiﬁcant reduction in mortality.
Edavarone has also shown to be protective in acute pancreatitis-
associated lung injury by suppression of IL-6 and TNF-α [175]. Fur-
thermore, it has been shown that edaravone suppressed bleomycin-
induced acute pulmonary injury in rabbits [176], and paraquat-
induced lung injury and ﬁbrosis in rats [177], and suppresses ﬁbrosis
in tight-skin and bleomycin-induced mouse models of systemic scle-
rosis [178]. This suggests an important role of edaravone in suppres-
sing skin and lung ﬁbrosis. The protective effect of edaravone
was demonstrated by its ability to inhibit lung injury and ﬁbrosis
via decreasing lipid peroxidation and the enhancing prostaglandin
E2 production in the experimental murine system. Another analog
MCI-186 (3-methyl-1-phenyl-pyrazolin-5-one) is shown to have pro-
tective effects against free radical damage, but is also shown have bi-
phasic effects on deterioration of pulmonary ﬁbrosis in mice [179].
Edaravone seems to be an interesting molecule which inhibits protein
carbonylation, which occurs in response to cigarette smoke and in pa-
tients with COPD. Hence, further studies are required to demonstrate
the therapeutic efﬁcacy of edaravone in management of COPD and its
symptoms.
8.2. Lazaroids (U75412E or tirilazad mesylate): a nonglucocorticoid
21-aminosteroid
Lazaroids (21-aminsteroids, U75412E or trilizad mesylate) are a
group of nonglucocorticoid analogues of methyl-prednisolone which
are able to penetrate hydrophobic regions of the cell membrane, spe-
ciﬁcally to prevent peroxidation of membrane lipids [180,181]. The
protective efﬁcacy of lazaroids has been reported in many animal
models of lung injury, such as injury by endotoxin [181], ischemic/re-
perfusion [182] and tobacco smoke [183]. The ﬁndings from the above
studies have revealed that lazaroids may exert their protective effect
by various mechanisms, inhibition of lipid peroxidation being the
main. In a cigarette smoke-induced lung injury model, it was found
that aerosolized lazaroids could inhibit the formation of free radicals
and also inhibit release of TNF-α in alveolar macrophages [184,185].
In another study, it was found that lazaroid U74389G was able to pro-
tect against hyperoxia in rat type-II pneumocytes [186]. Lazaroid,
U74006F was reported to protect against endotoxinmediated lung in-
jury in sheep and protected against antigen-induced bronchoconstric-
tion and bronchoalveolar eosinophilia in allergic sheep [187,188], and
sepsis-induced acute lung injury in minipigs [189]. Furthermore,
lazaroids were found to attenuate oxidant-induced lung injury by
inhibiting the mRNA expression for E-selectin, P-selectin, ICAM-1,
and VCAM-1 [190]. However, studies are required to evaluate the efﬁ-
cacy of lazaroids as therapeutic strategy in COPD, particularly in severe
COPD where steroid resistance occurs.
9. Conclusions
Oxidative stress is known to occur in the pathogenesis of COPD.
Targeting oxidative stress with pharmacological antioxidants or
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cial in the treatment and management of COPD. Several small mole-
cule antioxidant compounds have been investigated in clinical and
pre-clinical trials. Antioxidants, such as thiol molecules/donors, spin
traps, antioxidant enzyme mimetics, and inhibitors of oxidative stress
and lipid peroxidation and protein carbonylation blockers have po-
tential to be used in management and treatment of COPD, as well as
in different COPD phenotypes. However, the clinical trials so far
have been unsuccessful to clearly deﬁne (1) the type of antioxidant,
(2) regimen, and (3) time period of treatment in acute exacerbations
and pathogenesis of COPD. This is perhaps due to lack of understand-
ing of the pathophysiology of COPD and subtle differences in COPD
phenotypes. It is, therefore, important to identify the main source(s)
of oxidant in a particular phenotype and accordingly choose a partic-
ular antioxidant therapy or regimen for a given COPD phenotype.
Current therapy using antioxidants for COPD is symptomatic, e.g.
thiol-based therapy is mainly mucolytic (clearance of mucus, thereby
minimizing the bacterial/viral load). However, it is possible that antioxi-
dant therapy becomes therapeutic based on future studies involving
novel compounds in amelioration of COPD, particularly targeting smaller
airways. Furthermore, antioxidant compounds may also enhance the ef-
ﬁcacy of glucocorticoids by quenching anddetoxifying oxidants and alde-
hydes in COPD patients. Although thiol antioxidant treatments have
shown promising effects in targeting ROS and oxidant-mediated cellular
alterations, development of novel wide-spectrum small molecule antiox-
idantswith a good bioavailability and potency are needed in clinical trials
for COPD. Antioxidant therapy may affect important outcomes in COPD,
such as overcoming steroid resistance, mucus hypersecretion, inﬂamma-
tion and extracellular matrix remodeling. Furthermore, the effects of a
combination of various antioxidants along with thiols, spin traps, lipid
peroxidation/protein carbonylation inhibitors/blockers, or enzyme mi-
metics is an interesting proposition worth investigating in patients with
COPD. Antioxidants (e.g. thiols and other molecules) may be combined
with anti-inﬂammatories/PDE4 inhibitor/Sirtuin1 activator, bronchodila-
tors, steroids, antibiotics, and statins. Furthermore, novel antioxidant
strategies can be used as supplementing/pre-emptying agents in man-
agement of COPD.
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